{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:37:31Z","timestamp":1793072251133,"version":"4.5.0"},"reference-count":205,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 HL078825"],"award-info":[{"award-number":["P01 HL078825"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 HL113530"],"award-info":[{"award-number":["UM1 HL113530"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This review summarizes the results of clinical trials of cell therapy in patients with heart failure (HF). In contrast to acute myocardial infarction (where results have been consistently negative for more than a decade), in the setting of HF the results of Phase I\u2013II trials are encouraging, both in ischaemic and non-ischaemic cardiomyopathy. Several well-designed Phase II studies have met their primary endpoint and demonstrated an efficacy signal, which is remarkable considering that only one dose of cells was used. That an efficacy signal was seen 6\u201312\u2009months after a single treatment provides a rationale for larger, rigorous trials. Importantly, no safety concerns have emerged. Amongst the various cell types tested, mesenchymal stromal cells derived from bone marrow (BM), umbilical cord, or adipose tissue show the greatest promise. In contrast, embryonic stem cells are not likely to become a clinical therapy. Unfractionated BM cells and cardiosphere-derived cells have been abandoned. The cell products used for HF will most likely be allogeneic. New approaches, such as repeated cell treatment and intravenous delivery, may revolutionize the field. As is the case for most new therapies, the development of cell therapies for HF has been slow, plagued by multifarious problems, and punctuated by many setbacks; at present, the utility of cell therapy in HF remains to be determined. What the field needs is rigorous, well-designed Phase III trials. The most important things to move forward are to keep an open mind, avoid preconceived notions, and let ourselves be guided by the evidence.<\/jats:p>","DOI":"10.1093\/cvr\/cvab135","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T20:58:13Z","timestamp":1618606693000},"page":"951-976","source":"Crossref","is-referenced-by-count":90,"title":["Cell therapy in patients with heart failure: a comprehensive review and emerging concepts"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-8614","authenticated-orcid":false,"given":"Roberto","family":"Bolli","sequence":"first","affiliation":[{"name":"Institute of Molecular Cardiology, University of Louisville, 550 S. Jackson St., ACB, 3rd Floor, Louisville, KY 40292, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Solankhi","sequence":"additional","affiliation":[{"name":"Institute of Molecular Cardiology, University of Louisville, 550 S. Jackson St., ACB, 3rd Floor, Louisville, KY 40292, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-340X","authenticated-orcid":false,"given":"Xiang-Liang","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Molecular Cardiology, University of Louisville, 550 S. Jackson St., ACB, 3rd Floor, Louisville, KY 40292, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunpreet","family":"Kahlon","sequence":"additional","affiliation":[{"name":"Institute of Molecular Cardiology, University of Louisville, 550 S. Jackson St., ACB, 3rd Floor, Louisville, KY 40292, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"2022031721051502000_cvab135-B1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.117.029343","article-title":"Cardiomyocyte regeneration: a consensus statement","volume":"136","author":"Eschenhagen","year":"2017","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B3","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/eurheartj\/ehx248","article-title":"Global position paper on cardiovascular regenerative medicine","volume":"38","author":"Fernandez-Aviles","year":"2017","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ejhf.1767","article-title":"Time to end the war on cell therapy","volume":"22","author":"Bolli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022031721051502000_cvab135-B5","author":"Oransky"},{"key":"2022031721051502000_cvab135-B6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1139\/cjpp-2020-0406","article-title":"After the storm: an objective appraisal of the therapeutic efficacy of c-kit+ cardiac progenitor cells in preclinical models","volume":"99","author":"Bolli","year":"2021","journal-title":"Can J Phyiol Pharmacol"},{"key":"2022031721051502000_cvab135-B7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrcardio.2017.38","article-title":"Stem cells: cell therapy for cardiac repair: what is needed to move forward?","volume":"14","author":"Bolli","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022031721051502000_cvab135-B8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCRESAHA.118.311217","article-title":"Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions","volume":"123","author":"Banerjee","year":"2018","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B9","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/eurheartj\/ehv390","article-title":"Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial","volume":"36","author":"Hamshere","year":"2015","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2008.03.024","article-title":"Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"156","author":"Abdel-Latif","year":"2008","journal-title":"Am Heart J"},{"key":"2022031721051502000_cvab135-B11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00395-013-0346-0","article-title":"A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice","volume":"108","author":"Hong","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"2022031721051502000_cvab135-B12","doi-asserted-by":"crossref","first-page":"e96725","DOI":"10.1371\/journal.pone.0096725","article-title":"c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart","volume":"9","author":"Hong","year":"2014","journal-title":"PLoS One"},{"key":"2022031721051502000_cvab135-B13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/CIRCULATIONAHA.112.001075","article-title":"Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy","volume":"128","author":"Bolli","year":"2013","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/CIRCHEARTFAILURE.115.002210","article-title":"Effects of intracoronary infusion of escalating doses of cardiac stem cells in rats with acute myocardial infarction","volume":"8","author":"Tang","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2022031721051502000_cvab135-B15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.115.307647","article-title":"Long-term outcome of administration of c-kit(POS) cardiac progenitor cells after acute myocardial infarction: transplanted cells do not become cardiomyocytes, but structural and functional improvement and proliferation of endogenous cells persist for at least one year","volume":"118","author":"Tang","year":"2016","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCRESAHA.116.308937","article-title":"Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy","volume":"119","author":"Tokita","year":"2016","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B17","doi-asserted-by":"crossref","first-page":"e007400","DOI":"10.1161\/JAHA.117.007400","article-title":"Repeated administrations of cardiac progenitor cells are superior to a single administration of an equivalent cumulative dose","volume":"7","author":"Tang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022031721051502000_cvab135-B18","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.jacc.2017.01.048","article-title":"Myocardial reparative properties of cardiac mesenchymal cells isolated on the basis of adherence","volume":"69","author":"Wysoczynski","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00395-017-0606-5","article-title":"Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction","volume":"112","author":"Guo","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"2022031721051502000_cvab135-B20","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/stem.2198","article-title":"Preconditioning human cardiac stem cells with an HO-1 inducer exerts beneficial effects after cell transplantation in the infarcted murine heart","volume":"33","author":"Cai","year":"2015","journal-title":"Stem Cells"},{"key":"2022031721051502000_cvab135-B21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00395-011-0180-1","article-title":"Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models","volume":"106","author":"At the","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"2022031721051502000_cvab135-B22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s12015-020-10063-0","article-title":"Comparison of one and three intraventricular injections of cardiac progenitor cells in a murine model of chronic ischemic cardiomyopathy","volume":"17","author":"Guo","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"2022031721051502000_cvab135-B23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","article-title":"Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions","volume":"113","author":"Sanganalmath","year":"2013","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B24","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/CIRCRESAHA.116.305557","article-title":"\u201cString theory\u201d of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results","volume":"116","author":"Keith","year":"2015","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCRESAHA.118.313251","article-title":"New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types","volume":"123","author":"Wysoczynski","year":"2018","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/CIRCRESAHA.116.303614","article-title":"Use of mesenchymal stem cells for therapy of cardiac disease","volume":"116","author":"Karantalis","year":"2015","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCRESAHA.117.311578","article-title":"Lack of remuscularization following transplantation of human embryonic stem cell-derived cardiovascular progenitor cells in infarcted nonhuman primates","volume":"122","author":"Zhu","year":"2018","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B28","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/eurheartj\/ehz787","article-title":"A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair","volume":"41","author":"Wysoczynski","year":"2020","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B29","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCRESAHA.113.301720","article-title":"Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis","volume":"114","author":"Ismahil","year":"2014","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B31","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2020.03.019","article-title":"Myocardial interstitial fibrosis in nonischemic heart disease, part 3\/4: JACC focus seminar","volume":"75","author":"Ten","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nbt.3857","article-title":"A futile cycle in cell therapy","volume":"35","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2022031721051502000_cvab135-B33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamacardio.2018.4435","article-title":"A time to press reset and regenerate cardiac stem cell biology","volume":"4","author":"Epstein","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022031721051502000_cvab135-B34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41587-019-0042-1","article-title":"Regenerating the field of cardiovascular cell therapy","volume":"37","author":"Dog","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2022031721051502000_cvab135-B35","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B36","first-page":"1717","article-title":"Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial","volume":"307","author":"Very","year":"2012","journal-title":"JAMA"},{"key":"2022031721051502000_cvab135-B37","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"2022031721051502000_cvab135-B38","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(12)60195-0","article-title":"Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial","volume":"379","author":"Makkar","year":"2012","journal-title":"Lancet"},{"key":"2022031721051502000_cvab135-B39","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2013.02.071","article-title":"Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics","volume":"61","author":"Bartunek","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCRESAHA.115.304554","article-title":"Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy","volume":"115","author":"Henry","year":"2014","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.114.303180","article-title":"Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial","volume":"114","author":"Karantalis","year":"2014","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman","year":"2014","journal-title":"JAMA"},{"key":"2022031721051502000_cvab135-B43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2014.03.022","article-title":"Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE Trial","volume":"168","author":"Very","year":"2014","journal-title":"Am Heart J"},{"key":"2022031721051502000_cvab135-B44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijcard.2016.02.016","article-title":"Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: results of the MESAMI 1 pilot trial","volume":"209","author":"Pebble","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022031721051502000_cvab135-B45","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0140-6736(16)30137-4","article-title":"Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"2022031721051502000_cvab135-B46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ccd.26601","article-title":"The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction","volume":"89","author":"Henry","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"2022031721051502000_cvab135-B47","first-page":"648","article-title":"Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial","volume":"38","author":"Bartunek","year":"2017","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ebiom.2017.07.022","article-title":"Cardiac function improvement and bone marrow response: outcome analysis of the randomized PERFECT phase III clinical trial of intramyocardial CD133(+) application after myocardial infarction","volume":"22","author":"Steinhoff","year":"2017","journal-title":"EBioMedicine"},{"key":"2022031721051502000_cvab135-B49","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","article-title":"Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study)","volume":"121","author":"FLORA","year":"2017","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B50","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","article-title":"Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 Randomized Controlled Trial (RIMECARD trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy","volume":"121","author":"Bartolucci","year":"2017","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B51","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/sctm.17-0040","article-title":"Cryopreserved off-the-shelf allogeneic adipose-derived stromal cells for therapy in patients with ischemic heart disease and heart failure\u2014a safety study","volume":"6","author":"Kastrup","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2022031721051502000_cvab135-B52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jacc.2017.11.047","article-title":"Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction","volume":"71","author":"Menasch\u00e9","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13287-018-0969-z","article-title":"Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133(+) cells in ischemic refractory cardiomyopathy trial (RECARDIO","volume":"9","author":"Bassetti","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"2022031721051502000_cvab135-B54","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)","volume":"36","author":"Mathiasen","year":"2015","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B55","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.1700","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial","volume":"22","author":"Mathiasen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022031721051502000_cvab135-B56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3727\/096368916X692933","article-title":"ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial: rationale and design","volume":"26","author":"Chakravarty","year":"2017","journal-title":"Cell Transplant"},{"key":"2022031721051502000_cvab135-B57","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/eurheartj\/ehaa541","article-title":"Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial","volume":"41","author":"Makkar","year":"2020","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B58","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.4244\/EIJ-D-19-00035","article-title":"Allogeneic cardiosphere-derived cells for the treatment of heart failure with reduced ejection fraction: the Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells (DYNAMIC) trial","volume":"16","author":"Chakravarty","year":"2020","journal-title":"EuroIntervention"},{"key":"2022031721051502000_cvab135-B59"},{"key":"2022031721051502000_cvab135-B60","author":"Bolli"},{"key":"2022031721051502000_cvab135-B61","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.118.312978","article-title":"Rationale and design of the CONCERT-HF trial (Combination of Mesenchymal and c-kit(+) Cardiac Stem Cells As Regenerative Therapy for Heart Failure)","volume":"122","author":"Bolli","year":"2018","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCRESAHA.119.314951","article-title":"Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure","volume":"125","author":"Borow","year":"2019","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B63"},{"key":"2022031721051502000_cvab135-B64","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1161\/01.CIR.0000070596.30552.8B","article-title":"Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure","volume":"107","author":"Very","year":"2003","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B65","first-page":"II213","article-title":"Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy","volume":"110","author":"Very","year":"2004","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B66","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa051779","article-title":"Transcoronary transplantation of progenitor cells after myocardial infarction","volume":"355","author":"Assmus","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031721051502000_cvab135-B67","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cardfail.2010.11.007","article-title":"Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy","volume":"17","author":"Vrtovec","year":"2011","journal-title":"J Card Fail"},{"key":"2022031721051502000_cvab135-B68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.112.276519","article-title":"Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up","volume":"112","author":"Vrtovec","year":"2013","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B69","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1161\/CIRCULATIONAHA.112.000230","article-title":"Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"128","author":"Vrtovec","year":"2013","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B70","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/eurheartj\/ehv477","article-title":"Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study)","volume":"36","author":"Martino","year":"2015","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCRESAHA.116.309717","article-title":"Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial","volume":"120","author":"Butler","year":"2017","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B72","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1536\/ihj.16-328","article-title":"A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy","volume":"58","author":"Xiao","year":"2017","journal-title":"Int Heart J"},{"key":"2022031721051502000_cvab135-B74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCRESAHA.117.312170","article-title":"Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"123","author":"Vrtovec","year":"2018","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2018.02.009","article-title":"Rationale and design of the SENECA (StEm cell iNjECtion in cAncer survivors) trial","volume":"201","author":"Bolli","year":"2018","journal-title":"Am Heart J"},{"key":"2022031721051502000_cvab135-B76","first-page":"581","article-title":"Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial","volume":"2","author":"Bolli","year":"2020","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"2022031721051502000_cvab135-B77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCHEARTFAILURE.109.855023","article-title":"A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy","volume":"2","author":"Fischer-Rasokat","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2022031721051502000_cvab135-B78","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.111.067785","article-title":"Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial","volume":"125","author":"Ribeiro Dos Santos","year":"2012","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B79","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2022031721051502000_cvab135-B80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"2022031721051502000_cvab135-B81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/hc0102.101442","article-title":"Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart","volume":"105","author":"Taking","year":"2002","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B82","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI0214327","article-title":"Origin of endothelial progenitors in human postnatal bone marrow","volume":"109","author":"Reyes","year":"2002","journal-title":"J Clin Invest"},{"key":"2022031721051502000_cvab135-B83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/01.CIR.0000151812.86142.45","article-title":"Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model","volume":"111","author":"Silva","year":"2005","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4252\/wjsc.v9.i8.107","article-title":"Adipose-derived stromal cell in regenerative medicine: a review","volume":"9","author":"Tabatabaei Qomi","year":"2017","journal-title":"World J Stem Cells"},{"key":"2022031721051502000_cvab135-B85","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/sctm.19-0022","article-title":"Banking mesenchymal stromal cells from umbilical cord tissue: large sample size analysis reveals consistency between donors","volume":"8","author":"Raileanu","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"2022031721051502000_cvab135-B86","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13287-016-0465-2","article-title":"Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use","volume":"8","author":"Beloved","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"2022031721051502000_cvab135-B87","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"J Orthop Res"},{"key":"2022031721051502000_cvab135-B88","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.111.243147","article-title":"Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease","volume":"109","author":"Williams","year":"2011","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12929-018-0429-1","article-title":"Regenerative abilities of mesenchymal stem cells through mitochondrial transfer","volume":"25","author":"Paliwal","year":"2018","journal-title":"J Biomed Sci"},{"key":"2022031721051502000_cvab135-B90","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1152\/physrev.00019.2015","article-title":"Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue","volume":"96","author":"Golpanian","year":"2016","journal-title":"Physiol Rev"},{"key":"2022031721051502000_cvab135-B91","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.yjmcc.2010.08.005","article-title":"Paracrine mechanisms of stem cell reparative and regenerative actions in the heart","volume":"50","author":"Mirotsou","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"2022031721051502000_cvab135-B92","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri3209","article-title":"Multipotent mesenchymal stromal cells and the innate immune system","volume":"12","author":"The White","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2022031721051502000_cvab135-B93","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications","volume":"15","author":"Wang","year":"2014","journal-title":"Nat Immunol"},{"key":"2022031721051502000_cvab135-B94","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molmed.2011.10.004","article-title":"The immunomodulatory capacity of mesenchymal stem cells","volume":"18","author":"Gebler","year":"2012","journal-title":"Trends Mol Med"},{"key":"2022031721051502000_cvab135-B95","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/01.CIR.100.23.2380","article-title":"Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium","volume":"100","author":"Lim","year":"1999","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B96","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/01.CIR.84.4.1589","article-title":"Endothelium-dependent vasodilation is attenuated in patients with heart failure","volume":"84","author":"Kubo","year":"1991","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B97","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2020.03.020","article-title":"Extracellular matrix in ischemic heart disease, part 4\/4: JACC focus seminar","volume":"75","author":"Frangogiannis","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"At the","year":"2014","journal-title":"Cell Transplant"},{"key":"2022031721051502000_cvab135-B99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","article-title":"A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy","volume":"12","author":"Forbes","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022031721051502000_cvab135-B100","first-page":"1187","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Carousis","year":"2010","journal-title":"Arch Neurol"},{"key":"2022031721051502000_cvab135-B101","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022031721051502000_cvab135-B102","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"key":"2022031721051502000_cvab135-B103","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/stem.1638","article-title":"Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses","volume":"32","author":"Yin","year":"2014","journal-title":"Stem Cells"},{"key":"2022031721051502000_cvab135-B104","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.RES.0000122070.37999.1B","article-title":"Cardiac stem cells fail with aging: a new mechanism for the age-dependent decline in cardiac function","volume":"94","author":"Capogrossi","year":"2004","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B105","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/01.CIR.0000124476.32871.E3","article-title":"Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease","volume":"109","author":"Heeschen","year":"2004","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00395-016-0592-z","article-title":"Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials","volume":"112","author":"Contreras","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"2022031721051502000_cvab135-B107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/14779072.2015.1011621","article-title":"Allogeneic cardiac stem cell administration for acute myocardial infarction","volume":"13","author":"Crisostomo","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2022031721051502000_cvab135-B108","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction","volume":"54","author":"Hare","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B109","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"The White","year":"2008","journal-title":"Lancet"},{"key":"2022031721051502000_cvab135-B110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022031721051502000_cvab135-B111","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"2022031721051502000_cvab135-B112","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/qjmed\/hcw001","article-title":"A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema","volume":"109","author":"Stolk","year":"2016","journal-title":"Qjm"},{"key":"2022031721051502000_cvab135-B113","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/CIRCULATIONAHA.113.007412","article-title":"Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices","volume":"129","author":"Ash","year":"2014","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B114","doi-asserted-by":"crossref","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Then","year":"2012","journal-title":"PLoS One"},{"key":"2022031721051502000_cvab135-B115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2022031721051502000_cvab135-B116","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.117.310599","article-title":"Intravenously delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy","volume":"120","author":"Luger","year":"2017","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B117"},{"key":"2022031721051502000_cvab135-B118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2018.03.016","article-title":"The CardiAMP Heart Failure trial: a randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: trial rationale and study design","volume":"201","author":"Raval","year":"2018","journal-title":"Am Heart J"},{"key":"2022031721051502000_cvab135-B119","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1412","article-title":"Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)","volume":"21","author":"Paitazoglou","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022031721051502000_cvab135-B120"},{"key":"2022031721051502000_cvab135-B121"},{"key":"2022031721051502000_cvab135-B122","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jacc.2010.03.066","article-title":"Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction","volume":"56","author":"Behfar","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B123","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcyt.2019.04.056","article-title":"Umbilical cord-derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data","volume":"21","author":"Colicchia","year":"2019","journal-title":"Cytotherapy"},{"key":"2022031721051502000_cvab135-B124","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1634\/stemcells.2007-0637","article-title":"Concise review: mesenchymal stem\/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair\u2014current views","volume":"25","author":"Phinney","year":"2007","journal-title":"Stem Cells"},{"key":"2022031721051502000_cvab135-B125","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.5966\/sctm.2015-0022","article-title":"Chorion mesenchymal stem cells show superior differentiation, immunosuppressive, and angiogenic potentials in comparison with haploidentical maternal placental cells","volume":"4","author":"Gonz\u00e1lez","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"2022031721051502000_cvab135-B126","doi-asserted-by":"crossref","first-page":"e115316","DOI":"10.1371\/journal.pone.0115316","article-title":"Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"2022031721051502000_cvab135-B127","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.07.009","article-title":"Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance","volume":"79","author":"Kim","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022031721051502000_cvab135-B128","doi-asserted-by":"crossref","first-page":"37566","DOI":"10.1038\/srep37566","article-title":"Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF","volume":"6","author":"Deng","year":"2016","journal-title":"Sci Rep"},{"key":"2022031721051502000_cvab135-B129","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jcb.24057","article-title":"Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells","volume":"113","author":"Subramanian","year":"2012","journal-title":"J Cell Biochem"},{"key":"2022031721051502000_cvab135-B130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12015-012-9418-z","article-title":"The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord","volume":"9","author":"Bongso","year":"2013","journal-title":"Stem Cell Rev Rep"},{"key":"2022031721051502000_cvab135-B131","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/scrt477","article-title":"Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton's jelly derived mesenchymal stem cells? A comparative study","volume":"5","author":"Swamynathan","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"2022031721051502000_cvab135-B132","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.athoracsur.2006.10.066","article-title":"Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model","volume":"83","author":"Wu","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"2022031721051502000_cvab135-B133","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1875043501104010028","article-title":"Wharton's Jelly mesenchymal stem cells as off-the-shelf cellular therapeutics: a closer look into their regenerative and immunomodulatory properties","volume":"4","author":"Jyothi Prasanna","year":"2011","journal-title":"Open Tissue Eng Regen Med J"},{"key":"2022031721051502000_cvab135-B134","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/ten.teb.2013.0664","article-title":"Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?","volume":"20","author":"The Omar","year":"2014","journal-title":"Tissue Eng B Rev"},{"key":"2022031721051502000_cvab135-B135","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00395-011-0221-9","article-title":"Mesenchymal stromal cells mediate a switch to alternatively activated monocytes\/macrophages after acute myocardial infarction","volume":"106","author":"Dayan","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"2022031721051502000_cvab135-B136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/scrt394","article-title":"Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms","volume":"5","author":"Santos Nascimento","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"2022031721051502000_cvab135-B137","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.5966\/sctm.2015-0298","article-title":"Human umbilical cord-derived mesenchymal stromal cells improve left ventricular function, perfusion, and remodeling in a porcine model of chronic myocardial ischemia","volume":"5","author":"Liu","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"2022031721051502000_cvab135-B138","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.biomaterials.2011.11.059","article-title":"Vascularization and restoration of heart function in rat myocardial infarction using transplantation of human cbMSC\/HUVEC core-shell bodies","volume":"33","author":"Lee","year":"2012","journal-title":"Biomaterials"},{"key":"2022031721051502000_cvab135-B139","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13287-018-0888-z","article-title":"Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction","volume":"9","author":"Lim","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"2022031721051502000_cvab135-B140","doi-asserted-by":"crossref","first-page":"e49447","DOI":"10.1371\/journal.pone.0049447","article-title":"Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in alive","volume":"7","author":"Roura","year":"2012","journal-title":"PLoS One"},{"key":"2022031721051502000_cvab135-B141","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3727\/096368912X657675","article-title":"Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction","volume":"22","author":"Yannarelli","year":"2013","journal-title":"Cell Transplant"},{"key":"2022031721051502000_cvab135-B142","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1634\/stemcells.2006-0662","article-title":"The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro","volume":"25","author":"Nishiyama","year":"2007","journal-title":"Stem Cells"},{"key":"2022031721051502000_cvab135-B143","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MCA.0b013e3283640f00","article-title":"Wharton's jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction","volume":"24","author":"Zhang","year":"2013","journal-title":"Coron Artery Dis"},{"key":"2022031721051502000_cvab135-B144","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1089\/scd.2013.0119","article-title":"Grafts enriched with subamnion-cord-lining mesenchymal stem cell angiogenic spheroids induce post-ischemic myocardial revascularization and preserve cardiac function in failing rat hearts","volume":"22","author":"Martinez","year":"2013","journal-title":"Stem Cells Dev"},{"key":"2022031721051502000_cvab135-B145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13287-017-0472-y","article-title":"Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats","volume":"8","author":"Mao","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"2022031721051502000_cvab135-B146","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejcb.2015.11.003","article-title":"Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W) transgenic mouse of dilated cardiomyopathy","volume":"95","author":"Gong","year":"2016","journal-title":"Eur J Cell Biol"},{"key":"2022031721051502000_cvab135-B147","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijcard.2014.09.128","article-title":"Umbilical cord blood-derived mesenchymal stem cells: new therapeutic weapons for idiopathic dilated cardiomyopathy?","volume":"177","author":"Roura","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022031721051502000_cvab135-B148","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.4238\/2015.April.10.11","article-title":"Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure","volume":"14","author":"Zhao","year":"2015","journal-title":"Genet Mol Res"},{"key":"2022031721051502000_cvab135-B149","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12916-015-0399-z","article-title":"Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial","volume":"13","author":"Gao","year":"2015","journal-title":"BMC Med"},{"key":"2022031721051502000_cvab135-B150","first-page":"100","article-title":"Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf \u2018unlimited\u2019 therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study","volume":"11","author":"Musialek","year":"2015","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"2022031721051502000_cvab135-B151","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2174\/1381612821666141126100636","article-title":"Safety and efficacy of intracoronary human umbilical cord-derived mesenchymal stem cell treatment for very old patients with coronary chronic total occlusion","volume":"21","author":"At the","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2022031721051502000_cvab135-B152","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3892\/etm.2016.3748","article-title":"Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure","volume":"12","author":"Fang","year":"2016","journal-title":"Exp Ther Med"},{"key":"2022031721051502000_cvab135-B153","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s12015-015-9601-0","article-title":"Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A study protocol of a phase 1\/2, controlled and randomized trial in combination with coronary artery bypass grafting","volume":"11","author":"Can","year":"2015","journal-title":"Stem Cell Rev Rep"},{"key":"2022031721051502000_cvab135-B154","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jcyt.2017.08.004","article-title":"Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials","volume":"19","author":"Can","year":"2017","journal-title":"Cytotherapy"},{"key":"2022031721051502000_cvab135-B155","first-page":"212","article-title":"Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis","volume":"10","author":"Meng","year":"2018","journal-title":"Am J Transl Res"},{"key":"2022031721051502000_cvab135-B156","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12967-014-0253-7","article-title":"Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury","volume":"12","author":"Cheng","year":"2014","journal-title":"J Transl Med"},{"key":"2022031721051502000_cvab135-B157","first-page":"3441","article-title":"Human umbilical cord mesenchymal stem cell-loaded amniotic membrane for the repair of radial nerve injury","volume":"8","author":"At the","year":"2013","journal-title":"Neural Regen Res"},{"key":"2022031721051502000_cvab135-B158","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcyt.2014.09.010","article-title":"Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors","volume":"17","author":"Wang","year":"2015","journal-title":"Cytotherapy"},{"key":"2022031721051502000_cvab135-B159","first-page":"3241","article-title":"Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy","volume":"8","author":"Xie","year":"2016","journal-title":"Am J Transl Res"},{"key":"2022031721051502000_cvab135-B160","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022031721051502000_cvab135-B161","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1089\/scd.2013.0023","article-title":"Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy","volume":"22","author":"Wang","year":"2013","journal-title":"Stem Cells Dev"},{"key":"2022031721051502000_cvab135-B162","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3892\/etm.2016.3724","article-title":"Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis","volume":"12","author":"Hu","year":"2016","journal-title":"Exp Ther Med"},{"key":"2022031721051502000_cvab135-B163","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5009\/gnl17035","article-title":"Umbilical cord mesenchymal stem cell treatment for Crohn's disease: a randomized controlled clinical trial","volume":"12","author":"Zhang","year":"2018","journal-title":"Gut Liver"},{"key":"2022031721051502000_cvab135-B164","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","article-title":"Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation","volume":"34","author":"Gao","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022031721051502000_cvab135-B165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1507\/endocrj.EJ12-0343","article-title":"Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus","volume":"60","author":"Hu","year":"2013","journal-title":"Endocr J"},{"key":"2022031721051502000_cvab135-B166","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000071150","article-title":"Comparison of multi-lineage cells from human adipose tissue and bone marrow","volume":"174","author":"By Ugarte","year":"2003","journal-title":"Cells Tissues Organs"},{"key":"2022031721051502000_cvab135-B167","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.CIR.0000114522.38265.61","article-title":"Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives","volume":"109","author":"Planat-Benard","year":"2004","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B168","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/path.2469","article-title":"Why are MSCs therapeutic? New data: new insight","volume":"217","author":"Caplan","year":"2009","journal-title":"J Pathol"},{"key":"2022031721051502000_cvab135-B169","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1161\/01.CIR.0000121425.42966.F1","article-title":"Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells","volume":"109","author":"Rehman","year":"2004","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B170","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehm426","article-title":"Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction","volume":"28","author":"Valina","year":"2007","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B171","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm1391","article-title":"Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction","volume":"12","author":"Miyahara","year":"2006","journal-title":"Nat Med"},{"key":"2022031721051502000_cvab135-B172","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ejheart.2008.03.017","article-title":"Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction","volume":"10","author":"Small","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2022031721051502000_cvab135-B173","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1749-8090-6-43","article-title":"Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role","volume":"6","author":"Premaratne","year":"2011","journal-title":"J Cardiothorac Surg"},{"key":"2022031721051502000_cvab135-B174","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehx764","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","volume":"39","author":"Henry","year":"2018","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI63068","article-title":"Regenerating new heart with stem cells","volume":"123","author":"Antwerp","year":"2013","journal-title":"J Clin Invest"},{"key":"2022031721051502000_cvab135-B176","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(19)30542-2","article-title":"Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"2022031721051502000_cvab135-B177","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.109.871905","article-title":"Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction","volume":"121","author":"Tang","year":"2010","journal-title":"Circulation"},{"key":"2022031721051502000_cvab135-B178","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCRESAHA.115.306332","article-title":"A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure","volume":"117","author":"Very","year":"2015","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B179","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.RES.0000147315.71699.51","article-title":"Isolation and expansion of adult cardiac stem cells from human and murine heart","volume":"95","author":"Messina","year":"2004","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B180","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jacc.2011.11.029","article-title":"Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells","volume":"59","author":"At the","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B181","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCRESAHA.110.222703","article-title":"Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation","volume":"107","author":"Hatzistergos","year":"2010","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B182","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jacc.2015.08.879","article-title":"Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy","volume":"66","author":"Karantalis","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B183","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2017.09.036","article-title":"A combination of allogeneic stem cells promotes cardiac regeneration","volume":"70","author":"Natsumeda","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B184","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nbt.4162","article-title":"Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates","volume":"36","author":"Liu","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2022031721051502000_cvab135-B185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature13233","article-title":"Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts","volume":"510","author":"Chong","year":"2014","journal-title":"Nature"},{"key":"2022031721051502000_cvab135-B186","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.healun.2016.01.013","article-title":"Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure","volume":"35","author":"Kervadec","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2022031721051502000_cvab135-B187","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/eurheartj\/ehv189","article-title":"Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report","volume":"36","author":"Menasch\u00e9","year":"2015","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B188","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"2022031721051502000_cvab135-B189","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMp048045","article-title":"New human embryonic stem-cell lines\u2014more is better","volume":"350","author":"Gearhart","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031721051502000_cvab135-B190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMp048200","article-title":"Missed opportunities in embryonic stem-cell research","volume":"351","author":"Daley","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031721051502000_cvab135-B191","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJMp068206","article-title":"Stem-cell politics","volume":"355","author":"Okie","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031721051502000_cvab135-B192","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMp068180","article-title":"The politics and promise of stem-cell research","volume":"355","author":"Schwartz","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031721051502000_cvab135-B193","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1056\/NEJMp1105088","article-title":"Human embryonic stem-cell research under siege\u2014battle won but not the war","volume":"364","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031721051502000_cvab135-B194","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.scr.2014.06.005","article-title":"Cardiac regeneration using pluripotent stem cells\u2014progression to large animal models","volume":"13","author":"Chong","year":"2014","journal-title":"Stem Cell Res"},{"key":"2022031721051502000_cvab135-B195","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jacc.2017.11.042","article-title":"Trial of embryonic stem cell-derived cardiac progenitor cells: an encouraging start","volume":"71","author":"Miller","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022031721051502000_cvab135-B196","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/CIRCRESAHA.117.310710","article-title":"Repeated cell therapy: a paradigm shift whose time has come","volume":"120","author":"Bolli","year":"2017","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B197","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/CIRCRESAHA.118.314653","article-title":"Potential strategies for clinical translation of repeated cell therapy","volume":"124","author":"Vrtovec","year":"2019","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B198","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejheart.2008.05.010","article-title":"Effect of repeated intracoronary injection of bone marrow cells in patients with ischaemic heart failure the Danish stem cell study\u2014congestive heart failure trial (DanCell-CHF)","volume":"10","author":"Diederichsen","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2022031721051502000_cvab135-B199","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/eurjhf\/hfp062","article-title":"Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction","volume":"11","author":"Yao","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2022031721051502000_cvab135-B200","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1253\/circj.CJ-10-0898","article-title":"Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure\u2014a pilot study","volume":"75","author":"Gu","year":"2011","journal-title":"Circ J"},{"key":"2022031721051502000_cvab135-B201","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002740","article-title":"Repeated intramyocardial bone marrow cell injection in previously responding patients with refractory angina again improves myocardial perfusion, anginal complaints, and quality of life","volume":"8","author":"Mann","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2022031721051502000_cvab135-B202","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/eurheartj\/ehv559","article-title":"Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT","volume":"37","author":"Assmus","year":"2016","journal-title":"Eur Heart J"},{"key":"2022031721051502000_cvab135-B203","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/CIRCRESAHA.114.304792","article-title":"Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials","volume":"117","author":"Afzal","year":"2015","journal-title":"Circ Res"},{"key":"2022031721051502000_cvab135-B204","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cardfail.2016.08.002","article-title":"Electroanatomic properties of the myocardium predict response to CD34+ cell therapy in patients with ischemic and nonischemic heart failure","volume":"23","author":"Zemljic","year":"2017","journal-title":"J Card Fail"},{"key":"2022031721051502000_cvab135-B205","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1093\/eurheartj\/ehaa802","article-title":"Cell therapy for acute myocardial infarction: requiescat in pace","volume":"41","author":"Bolli","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvab135\/38337429\/cvab135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/4\/951\/42950209\/cvab135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/4\/951\/42950209\/cvab135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T23:46:03Z","timestamp":1647560763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/118\/4\/951\/6237881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":205,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2022,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvab135","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,4,19]]}}}